A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living donor liver transplants

drug protocol number
CRAD001H2307
drug sponsor
Novartis
drug study
Everolimus + reduced tacrolimus VS.Tacrolimus
drug trial site
KFSH & RC-R
drug status
Completed
drug phase